Form 8-K - Current report:
SEC Accession No. 0001140361-25-026853
Filing Date
2025-07-23
Accepted
2025-07-23 08:15:27
Documents
13
Period of Report
2025-07-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20052404_8k.htm   iXBRL 8-K 34515
2 EXHIBIT 99.1 ef20052404_ex99-1.htm EX-99.1 15571
  Complete submission text file 0001140361-25-026853.txt   184074

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ird-20250722.xsd EX-101.SCH 3859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20250722_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20250722_pre.xml EX-101.PRE 16041
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20052404_8k_htm.xml XML 4051
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 251141670
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)